Valneva's 2024 Registration Document Submission and Overview
Valneva SE Files Its 2024 Registration Document
Valneva SE, a company known for its innovative vaccines, has recently filed its 2024 Universal Registration Document (URD) alongside the US Form 20-F. This key filing highlights the company's ongoing commitment to transparency and regulatory compliance.
The announcement, made on a recent date in March, reveals that Valneva submitted the URD to the French Financial Markets Authority (AMF) and the Form 20-F to the U.S. Securities and Exchange Commission (SEC). This marks an important step in sharing crucial information about the company with stakeholders and the investing public.
Contents of the Universal Registration Document
The 2024 Universal Registration Document provides a comprehensive overview of Valneva’s financials and operations. It contains several essential reports, including the company's Annual Financial Report and the Annual Management Report. Additionally, the document features the Corporate Governance Report, highlighting the governance practices within Valneva, ensuring that it operates with the highest standards of integrity and accountability.
Included in the URD is an in-depth Sustainability Statement, which is an essential part of Valneva’s commitment to corporate social responsibility. This statement outlines the company's initiatives designed to contribute positively to public health and global challenges.
Availability of Documents
Valneva has made these significant documents accessible on its official website. Interested parties can view the URD and the Form 20-F, affirming Valneva's dedication to maintaining open lines of communication with investors and stakeholders.
Furthermore, these filings will be available on the AMF and SEC websites. For those wishing to obtain hard copies, Valneva offers these documents free of charge upon request, which can be made through their official contact address.
About Valneva SE
Valneva SE is at the forefront of developing vaccines for infectious diseases, addressing significant unmet medical needs. Their specialized approach leverages extensive expertise across various vaccine modalities, enabling the development of groundbreaking solutions.
The company's success is reflected in its ability to advance multiple vaccines from early research to market approval. Currently, Valneva markets several proprietary travel vaccines, including a pioneering chikungunya vaccine, and collaborates with partners on third-party vaccine products.
Valneva's pipeline is bolstered by revenues generated from their commercial business, which supports further advancements in vaccine development. Among its noteworthy projects is the only Lyme disease vaccine candidate in advanced clinical stages, partnered with Pfizer. The company is also actively developing vaccines targeting Zika virus and other public health threats.
Investor and Media Contacts
For inquiries related to investments or media, Valneva SE offers direct communication lines. Those interested can reach out to Laetitia Bachelot-Fontaine, the VP of Global Communications, or Joshua Drumm, Ph.D., the VP of Global Investor Relations. Both are readily available to provide insights or address any concerns regarding the company.
Frequently Asked Questions
What is the purpose of the 2024 Universal Registration Document?
The URD contains essential financial and corporate governance information about Valneva, promoting transparency to investors and stakeholders.
What types of reports are included in the document?
The URD includes the Annual Financial Report, Annual Management Report, Corporate Governance Report, and a Sustainability Statement.
How can I access Valneva's filings?
Valneva's filings are available on their official website, as well as the AMF and SEC websites for wider access.
What kind of vaccines does Valneva develop?
Valneva specializes in prophylactic vaccines, including travel vaccines and pioneering solutions for infectious diseases with unmet medical needs.
Who can I contact for investor relations at Valneva?
Inquiries regarding investments can be directed to Laetitia Bachelot-Fontaine or Joshua Drumm, who manage global communications and investor relations, respectively.
About The Author
Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.